2026-10-14T13:11:12Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33764905 2026-09-30T00:03:03Z category_7 portal_333 item_type_11 month_year_09_2026

Enlicitide: First Approval Hannah A. Blair (13864794) Medicine Enlicitide Hypercholesterolaemia review Adis Insight Report DeclarationsAuthorship and Conflict of interest During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Hannah A. Blair is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.Additional information about this Adis Drug Review can be found <a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews" target="_blank">here</a>.AbstractEnlicitide (LIPFENDRA®) is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor being developed by Merck Sharp & Dohme for the treatment of dyslipidaemias. On 16 July 2026, enlicitide received its first approval in the USA where it is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia (HeFH). This article summarizes the milestones in the development of enlicitide leading to this first approval for hypercholesterolaemia.© Springer Nature Switzerland AG 2026 2026-09-30T00:03:03Z Text Online resource 10.6084/m9.figshare.33764905.v1 https://figshare.com/articles/online_resource/Enlicitide_First_Approval/33764905 CC BY-NC 4.0